Smith+Nephew

Smith+Nephew is a global medical technology company that designs and manufactures technology for the repair, regeneration and replacement of soft and hard tissue. Founded in 1856 in Hull, England, where it began as a small pharmacy, it now employs more than 18,000 people and operates in over 100 countries, serving millions of patients annually. The company is listed on the London Stock Exchange, where it is a FTSE 100 constituent, and on the New York Stock Exchange.

Its work is organised around three global business units: Orthopaedics, Sports Medicine + ENT, and Advanced Wound Management. Technical domains span orthopaedic implants, robotics-assisted surgery, bioinductive implants, negative pressure wound therapy and wider wound management. Products include the CORI Surgical System, a robotics-assisted surgery platform; PICO, a negative pressure wound therapy system; and the REGENETEN Bioinductive Implant for tendon and soft tissue repair.

The company states its mission as restoring people's bodies and their self-belief by using technology to take the limits off living, with a stated focus on reducing the human and economic cost of wounds for patients. Its technology is used across orthopaedics, sports medicine, ENT and advanced wound management, and in professional sport: the company supports elite athletes including UFC's Tom Aspinall in recovery from career-threatening injuries.